Skip to main content

Recent News

  • Dec 03, 2021
    RheumNow Podcast square
    In spite of the transformative growth of telemedicine during the COVID-19 pandemic, rheumatologists use of telemedicine is waning, much like the use of masks. Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology.
    Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Spondyloarthritis Panel Discussion: ACR21 Meeting Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood discuss abstracts #0562, #1919, #0907, #0364 and #0919 @synovialjoints @doctorRBC @uptoTate @RHEUMarampa @AkhilSoodMD https://t.co/g0ARcP26wt https://t.co/8Lpwpf6AI1
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
Watch Now: Can We Stop Medication in Systemic JIA?https://t.co/yRIb70YVME https://t.co/EJ2PmC6xKY
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
Third Time's the Charm - COVID Vaccination While on Rituximabhttps://t.co/3j0KeQtzw1 https://t.co/YvgpaDX7tv
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies.https://t.co/T1feTkSKQv https://t.co/XElvgsGC0E
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
Best of PsA Day 4 - MACE in PsAhttps://t.co/NTM1GR7d5W https://t.co/ZxPJ8jDXhD
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
Watch: Rheumatic Diseases Can Take your Breath Awayhttps://t.co/7Butbt50N3 https://t.co/4VV1myDXWV
Dr. John Cush @RheumNow (  View Tweet)
Dec 03, 2021
dementia,brain

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Dec 02, 2021

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..

This makes sense when you see that dementia in RA is associated with age, prior cardiovascular and cerebrovascular events and the severity of joint involvement.

Read Article
liver.jpg

Methotrexate and hepatic fibrosis: we must be doing something right

Dec 02, 2021

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in rheumatology, and the consequent frequency of patient counselling about it, relatively little is known about what precautions are absolutely required, a situation which might otherwise provoke anxiety for patients.

Read Article
Might Tofacitinib Reduce Malignancy Risk with Patients with RA?https://t.co/xDnbPvjFDj https://t.co/yVcftm9Vwz
Dr. John Cush @RheumNow (  View Tweet)
Dec 02, 2021
Watch: TNFi in axSpAhttps://t.co/uS01KNDgIH https://t.co/eb0W3fBKhq
Dr. John Cush @RheumNow (  View Tweet)
Dec 02, 2021
uveitis eye iritis

New Insights into Uveitis in Spondyloarthritis

Dec 01, 2021

Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). The prevalence of uveitis in axSpA is between 25-30%. Up to 50% of patients with an acute episode of uveitis develop recurrent anterior uveitis or iritis. Being such a prevalent EAM in axSpA, we should focus on this condition. There have been some updates on uveitis in SpA at #ACR21 which I will share here.

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter study reports that drug hypersensitivity and pulmonary reactions in Still's patients receiving IL-1 or IL-6 inhibitors is strongly associated with HLA-

Read Article
Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.https://t.co/7nncosDjO3 https://t.co/hnltnnMkrm
Dr. John Cush @RheumNow (  View Tweet)
Dec 01, 2021
Pediatric Psoriatic Arthritis: Dr. Eric Ruderman ( @JointMD) discusses abstracts #1424 presented at the ACR21 annual meeting.https://t.co/aRCPAlBGev https://t.co/jsa261ZuYx
Dr. John Cush @RheumNow (  View Tweet)
Dec 01, 2021
"Doctor, I Can Tell When It's Raining!" Dr. Najm ( @AurelieRheumo) discusses abstract #1912 presented at the ACR21 annual meeting.https://t.co/ZMY0Btmdt1 https://t.co/H9mVnt2Kdi
Dr. John Cush @RheumNow (  View Tweet)
Dec 01, 2021
Urine Proteome Advances: What Do They Mean?https://t.co/rfIUThDF93 https://t.co/CcUleDW2aM
Dr. John Cush @RheumNow (  View Tweet)
Dec 01, 2021
Medication Preferences in Patients with Psoriatic Arthritishttps://t.co/t88Kgn28F7 https://t.co/kVVd4GXd99
Dr. John Cush @RheumNow (  View Tweet)
Dec 01, 2021
Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Nov 30, 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Guselkemab vs. Ustekinumab in PsAhttps://t.co/YJ8M3byZg6 https://t.co/wxSpkvnb84
Dr. John Cush @RheumNow (  View Tweet)
Nov 30, 2021
×